Gilead Sciences: Mark Genovese, SVP of inflammation
Gilead Sciences has tapped Mark Genovese to serve as senior vice president of inflammation. In his new role, Genovese will oversee the clinical development of the company’s investigational portfolio of treatments for inflammatory conditions.
Genovese had been on the faculty of Stanford University for more than 21 years, most recently as the James W. Raitt Professor of Medicine and Clinical Chief in the Division of Immunology and Rheumatology. At the university, he established a clinical research program focused on translational medicine in autoimmune diseases and led numerous investigator-initiated studies and international multi-center trials for the treatment of rheumatological diseases, including arthritis.